Search Result

Results for "

mitophagy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Mitophagy (24) Adiponectin Receptor (1) Aldose Reductase (1) AMPK (2) Antibiotic (2) Apoptosis (9) AUTACs (2) Autophagy (19) Bacterial (2) CRISPR/Cas9 (1) Deubiquitinase (3) Dynamin (1) Endogenous Metabolite (2) GSK-3 (1) HSV (1) Influenza Virus (2) Isotope-Labeled Compounds (2) JAK (1) MEK (2) Mitochondrial Metabolism (2) mTOR (2) Organoid (2) P2X Receptor (1) p38 MAPK (2) p62 (1) Parasite (1) PARP (3) PINK1/Parkin (4) Prolyl Endopeptidase (PREP) (2) Wnt (1) YAP (2) β-catenin (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (8)

By Targets:

Mitophagy (24)

Adiponectin Receptor (1)

Aldose Reductase (1)

AMPK (2)

Antibiotic (2)

Apoptosis (9)

AUTACs (2)

Autophagy (19)

Bacterial (2)

CRISPR/Cas9 (1)

Deubiquitinase (3)

Dynamin (1)

Endogenous Metabolite (2)

GSK-3 (1)

HSV (1)

Influenza Virus (2)

Isotope-Labeled Compounds (2)

JAK (1)

MEK (2)

Mitochondrial Metabolism (2)

mTOR (2)

Organoid (2)

P2X Receptor (1)

p38 MAPK (2)

p62 (1)

Parasite (1)

PARP (3)

PINK1/Parkin (4)

Prolyl Endopeptidase (PREP) (2)

Wnt (1)

YAP (2)

β-catenin (1)

By Research Areas:

Cancer (25)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (8)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Mitophagy

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-115576

*P62-mediated mitophagy* inducer** 3 Publications Verification PMI	p62 Mitophagy Autophagy	Neurological Disease Cancer
P62-mediated mitophagy inducer (PMI) is a P62-mediated mitophagy activator. P62-mediated mitophagy inducer activates mitochondrial autophagy without recruitment of Parkin or collapse of the mitochondrial membrane potential and remains active in cells lacking a fully functional PINK1/Parkin pathway. P62-mediated mitophagy inducer serves as a pharmacological tool to study the molecular mechanisms of mitosis, avoiding toxicity and some of the non-specific effects associated with the sudden dissipation of mitochondria lacking membrane potential .

HY-141659

CMPD-39 1 Publications Verification	Deubiquitinase	Cancer
CMPD-39 is a selective USP30 inhibitor with an IC₅₀ of 0.02 μM. CMPD-39 increases protein ubiquitination and accelerates mitophagy .

HY-162325

WJ-39	Aldose Reductase Mitochondrial Metabolism Apoptosis Mitophagy	Metabolic Disease
WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis .

HY-163172

Miro1 Reducer	Others	Neurological Disease
Miro1 Reducer is a small molecule that can repair this defect of Miro1 in Parkinson's disease (PD) fibroblasts. Miro1 Reducer reduces the delayed mitophagy phenotype in PD fibroblasts. Miro1 Reducer reduces Miro1 protein levels in dose-dependent manner (IC₅₀ = 7.8 mM) .

HY-152265

PARL-IN-1	PINK1/Parkin Mitophagy	Neurological Disease
PARL-IN-1 is a potent PARL inhibitor with an IC₅₀ value of 28 nM. PARL-IN-1 inhibits PARL and leads to a robust activation of the PINK1/Parkin pathway. PARL-IN-1 promotes PINK1/Parkin-dependent mitophagy .

HY-152943

MTK458 EP-0035985	PINK1/Parkin Mitophagy Mitochondrial Metabolism	Neurological Disease Cancer
MTK458 is an orally active brain penetrant PINK1 activator. MTK458 binds to PINK1 and stabilizes an active heterocomplex, thereby increasing mitophagy. MTK458 can be used for research on Parkinson's disease .

HY-147225

TSPO Ligand-Linker Conjugates 1	AUTACs Mitophagy	Neurological Disease Metabolic Disease Cancer
TSPO Ligand-Linker Conjugates 1 contains a ligand for translocator protein (TSPO) and a linker, which is used for the synthesis of mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC can bind the TSPO on the outer mitochondrial membrane (OMM) of mitochondria and degrades impaired mitochondria and proteins via *mitophagy*, and improves mitochondrial activity. TSPO Ligand-Linker Conjugates 1 can be used in mitochondrial dysfunction related research, including neurodegenerative diseases, cancer, and diabetes .

HY-153089

GSK3-IN-3 1 Publications Verification	GSK-3 Mitophagy	Neurological Disease
GSK3-IN-3 is a *mitophagy* inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC₅₀ value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA .

HY-152943A

(Rac)-MTK458

(Rac)-EP-0035985
Mitophagy Cancer

(Rac)-MTK458 (compound 16) is an activator of mitophagy. EP-0035985 is the isomer of EP-0035985 .

(Rac)-MTK458 (Rac)-EP-0035985	Mitophagy	Cancer
(Rac)-MTK458 (compound 16) is an activator of *mitophagy*. EP-0035985 is the isomer of EP-0035985 .

HY-15886

Mdivi-1 125+ Cited Publications Mitochondrial division inhibitor 1	Dynamin Mitophagy Autophagy Apoptosis	Cancer
Mdivi-1 is a selective dynamin-related protein 1 (Drp1) inhibitor. Mdivi-1 is a mitochondrial division/mitophagy inhibitor.

HY-112438

MF-094 3 Publications Verification	Deubiquitinase	Cancer
MF-094 is a potent and selective USP30 inhibitor with an IC₅₀ of 120 nM. MF-094 increases protein ubiquitination and accelerates mitophagy .

HY-134640

AUTAC4 1 Publications Verification	AUTACs Mitophagy	Neurological Disease Cancer
AUTAC4 is a mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC4 downregulates cytosolic proteins and promotes targeted mitochondrial turnover via *mitophagy* .

HY-13417A

AICAR phosphate 120+ Cited Publications Acadesine phosphate; AICA Riboside phosphate	AMPK Autophagy YAP Mitophagy Endogenous Metabolite	Cancer
AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and *mitophagy* inhibitor .

HY-13417

AICAR 120+ Cited Publications Acadesine; AICA Riboside	AMPK Autophagy YAP Mitophagy Endogenous Metabolite	Cancer
AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an autophagy, YAP and *mitophagy* inhibitor .

HY-12031A

U0126 330+ Cited Publications	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and *mitophagy* inhibitor .

HY-10162

Olaparib 180+ Cited Publications AZD2281; KU0059436	PARP Autophagy Mitophagy	Cancer
Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and *mitophagy* activator .

HY-N0109

Salidroside 15+ Cited Publications Rhodioloside	PINK1/Parkin mTOR Apoptosis Prolyl Endopeptidase (PREP)	Cancer
Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.

HY-12031

U0126-EtOH 330+ Cited Publications	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and *mitophagy* inhibitor .

HY-N0484

Liensinine 5+ Cited Publications	Autophagy Mitophagy Apoptosis	Cardiovascular Disease Cancer
Liensinine is an *autophagy/mitophagy* inhibitor. Liensinine, a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn, has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc .

HY-10162S1

Olaparib-d8 AZD2281-d₈; KU0059436-d₈	PARP Autophagy Mitophagy	Cancer
Olaparib-d₈ is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-10162S3

Olaparib-d4-1 AZD2281-d₄-1; KU0059436-d₄-1	Isotope-Labeled Compounds PARP Autophagy Mitophagy	Cancer
Olaparib-d₄-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-50856

Ruxolitinib 115+ Cited Publications INCB18424	JAK Autophagy Mitophagy Apoptosis	Cancer
Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic *mitophagy* .

HY-16592

Brefeldin A 60+ Cited Publications BFA; Cyanein; Decumbin	Autophagy CRISPR/Cas9 Mitophagy HSV Antibiotic Bacterial	Infection Cancer
Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking. Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus . Brefeldin A is also an autophagy and *mitophagy* inhibitor . Brefeldin A is a CRISPR/Cas9 activator . Brefeldin A inhibits HSV-1 and has anti-cancer activity .

HY-N0109R

Salidroside (Standard) Rhodioloside (Standard)	Prolyl Endopeptidase (PREP) mTOR Apoptosis PINK1/Parkin	Cancer
Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy .

HY-160019

MTX115325	Deubiquitinase Mitophagy	Neurological Disease
MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC₅₀=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC₅₀=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .

HY-N0485

Liensinine Diperchlorate 5+ Cited Publications	Autophagy Mitophagy	Cardiovascular Disease
Liensinine Diperchlorate is a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn. Liensinine Diperchlorate inhibits late-stage *autophagy/mitophagy* through blocking autophagosome-lysosome fusion. Liensinine Diperchlorate has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc .

HY-150636

Autophagy-IN-1	Autophagy Apoptosis	Cancer
Autophagy-IN-1 is a potent *autophagy/mitophagy* inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer .

HY-162344

Ir-CA	Apoptosis Autophagy	Cancer
Ir-CA is an antitumor agent. Ir-CA can accumulate in mitochondria and induces mitochondria dysfunction. Ir-CA induces apoptosis and autophagy. Ir-CA initiates mitophagy and cell cycle arrest to kill Cisplatin (HY-17394)-resistant A549R cells. Ir-CA can effectively inhibit metastasis by inhibiting MMP-2/MMP-9 .

HY-13417S

AICAR-13C2,15N Acadesine-¹³C₂,¹⁵N; AICA Riboside-¹³C₂,¹⁵N	Isotope-Labeled Compounds	Others
AICAR- ¹³C₂, ¹⁵N (Acadesine- ¹³C₂, ¹⁵N; AICA Riboside- ¹³C₂, ¹⁵N)is the ¹³C and ¹⁵N labeledAICAR(HY-13417) . AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an autophagy, YAP and *mitophagy* inhibitor .

HY-10256A

Adezmapimod hydrochloride Maximum Cited Publications 400 Publications Verification SB 203580 hydrochloride; RWJ 64809 hydrochloride	Organoid p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride is an autophagy and *mitophagy* activator .

HY-15597

Salinomycin 20+ Cited Publications Procoxacin	Bacterial Wnt β-catenin Mitophagy Autophagy Apoptosis Antibiotic Parasite	Cancer
Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of gram-positive bacteria. Salinomycin is a potent inhibitor of Wnt/β-catenin signaling, blocks Wnt-induced LRP6 phosphorylation. Salinomycin (Procoxacin) shows selective activity against human cancer stem cells .

HY-N9182

Zeaxanthin dipalmitate Physalien	Adiponectin Receptor P2X Receptor Autophagy	Inflammation/Immunology
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (K_d=81.2 nM) and adiponectin receptor 1 (AdipoR1; K_d=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .

HY-10256

Adezmapimod Maximum Cited Publications 400 Publications Verification SB 203580; RWJ 64809	Organoid p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and *mitophagy* activator .

Cat. No.	Product Name

HY-L089

Mitochondria-Targeted Compound Library	890 compounds
Mitochondria plays an important role in many vital processes in cells, including energy production, fatty-acid oxidation and the Tricarboxylic Acid (TCA) cycle, calcium signaling, permeability transition, apoptosis and heat production. At present, it is recognized that many diseases are associated with impaired mitochondrial function, such as increased accumulation of ROS and decreased OXPHOS and ATP production. Mitochondria are recognized as one of the most important targets for new drug design in cancer, cardiovascular, and neurological diseases, etc. Some small molecule drugs or biologics can act on mitochondria through various pathways, including ETC inhibition, OXPHOS uncoupling, mitochondrial Ca²⁺ modulation, and control of oxidative stress via decrease or increase of mitochondrial ROS accumulation. MCE supplies a unique collection of 890 mitochondria-targeted compound that mainly targeting Mitochondrial Metabolism, ATP Synthase, Mitophagy, Reactive Oxygen Species, etc. MCE Mitochondria-Targeted Compound Library is a useful tool for mitochondria-targeted drug discovery and related research.

Mitochondria-Targeted Compound Library

890 compounds

Mitochondria plays an important role in many vital processes in cells, including energy production, fatty-acid oxidation and the Tricarboxylic Acid (TCA) cycle, calcium signaling, permeability transition, apoptosis and heat production. At present, it is recognized that many diseases are associated with impaired mitochondrial function, such as increased accumulation of ROS and decreased OXPHOS and ATP production. Mitochondria are recognized as one of the most important targets for new drug design in cancer, cardiovascular, and neurological diseases, etc. Some small molecule drugs or biologics can act on mitochondria through various pathways, including ETC inhibition, OXPHOS uncoupling, mitochondrial Ca²⁺ modulation, and control of oxidative stress via decrease or increase of mitochondrial ROS accumulation.

MCE supplies a unique collection of 890 mitochondria-targeted compound that mainly targeting Mitochondrial Metabolism, ATP Synthase, Mitophagy, Reactive Oxygen Species, etc. MCE Mitochondria-Targeted Compound Library is a useful tool for mitochondria-targeted drug discovery and related research.

HY-L034

Anti-Aging Compound Library	4352 compounds
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. MCE Anti-Aging Compound Library contains 4352 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Anti-Aging Compound Library

4352 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 4352 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Cat. No.	Product Name	Category	Target	Chemical Structure